Abstract
Background: Repeated administrations of insulin injection on daily basis evoke pain and numerous complications with adverse effects on the diabetic patients’ life quality. Moreover, wearing insulin pump is also associated with several problems of diabetic ketoacidosis, catheter site infection, contact dermatitis and high cost.
Method: We have developed an in situ gel system, consisting of insulin-loaded liposomes dispersed within a thermoreversible gel (Pluronic® F127 gel), which increases the duration of insulin action for the treatment of diabetes. Vesicular phospholipid gel technique was used to encapsulate the insulin into liposomes.
Results: The resulting liposomal gel formulation had a longer drug-release period in vitro than a free insulin solution or liposomes and Pluronic® F127 gel individually. Furthermore, the addition of liposomes to the Pluronic® F127 gel improved the stability of the encapsulated insulin at a physiological temperature. In vivo study was performed to investigate the bioactivity and absorption of insulin released from the liposomal gel and other formulations. The liposomal gel released insulin into the bloodstream continuously for up to 7 days and significantly enhanced drug bioavailability compared to insulin released from liposomes or Pluronic® F127 gel individually. Blood glucose levels were reduced for up to 4 days. Histology data demonstrated excellent biocompatibility of the Pluronic® F127 gel-based delivery systems, with no observable inflammatory response in rat subcutaneous tissues.
Conclusion: Obtained results show that the insulin-loaded liposomes dispersed within Pluronic® F127 gel can be used as a long-acting drug delivery system, and replacement for conventional insulin therapy.
Keywords: Insulin, Liposome, thermoreversible gel, controlled release, subcutaneous administration, diabetes mellitus.
Current Pharmaceutical Design
Title:Long-lasting Insulin Treatment Via a Single Subcutaneous Administration of Liposomes in Thermoreversible Pluronic® F127 Based Hydrogel
Volume: 23 Issue: 39
Author(s): Xiaoyu Chen, Blenda Chi Kwan Wong, Hubiao Chen, Shiping Zhang, Zhaoxiang Bian, Ge Zhang, Congcong Lin, Muhammad Kashif Riaz, Deependra Tyagi, Aiping Lu*Zhijun Yang*
Affiliation:
- School of Chinese Medicine, Hong Kong Baptist University, 7 Baptist University Road, Kowloon Tong, Kowloon, Hong Kong,China
- School of Chinese Medicine, Hong Kong Baptist University, 7 Baptist University Road, Kowloon Tong, Kowloon, Hong Kong,China
Keywords: Insulin, Liposome, thermoreversible gel, controlled release, subcutaneous administration, diabetes mellitus.
Abstract: Background: Repeated administrations of insulin injection on daily basis evoke pain and numerous complications with adverse effects on the diabetic patients’ life quality. Moreover, wearing insulin pump is also associated with several problems of diabetic ketoacidosis, catheter site infection, contact dermatitis and high cost.
Method: We have developed an in situ gel system, consisting of insulin-loaded liposomes dispersed within a thermoreversible gel (Pluronic® F127 gel), which increases the duration of insulin action for the treatment of diabetes. Vesicular phospholipid gel technique was used to encapsulate the insulin into liposomes.
Results: The resulting liposomal gel formulation had a longer drug-release period in vitro than a free insulin solution or liposomes and Pluronic® F127 gel individually. Furthermore, the addition of liposomes to the Pluronic® F127 gel improved the stability of the encapsulated insulin at a physiological temperature. In vivo study was performed to investigate the bioactivity and absorption of insulin released from the liposomal gel and other formulations. The liposomal gel released insulin into the bloodstream continuously for up to 7 days and significantly enhanced drug bioavailability compared to insulin released from liposomes or Pluronic® F127 gel individually. Blood glucose levels were reduced for up to 4 days. Histology data demonstrated excellent biocompatibility of the Pluronic® F127 gel-based delivery systems, with no observable inflammatory response in rat subcutaneous tissues.
Conclusion: Obtained results show that the insulin-loaded liposomes dispersed within Pluronic® F127 gel can be used as a long-acting drug delivery system, and replacement for conventional insulin therapy.
Export Options
About this article
Cite this article as:
Chen Xiaoyu , Wong Chi Kwan Blenda , Chen Hubiao , Zhang Shiping, Bian Zhaoxiang , Zhang Ge, Lin Congcong , Riaz Kashif Muhammad, Tyagi Deependra , Lu Aiping *, Yang Zhijun*, Long-lasting Insulin Treatment Via a Single Subcutaneous Administration of Liposomes in Thermoreversible Pluronic® F127 Based Hydrogel, Current Pharmaceutical Design 2017; 23 (39) . https://dx.doi.org/10.2174/1381612823666170509123844
DOI https://dx.doi.org/10.2174/1381612823666170509123844 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Insulin Therapy: Going The "Smarter" Way
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Death by Insulin: Management of Self-Harm and Suicide in Diabetes Management
Current Diabetes Reviews Weight Gain and Metabolic Changes During Treatment with Antipsychotics and Antidepressants
Endocrine, Metabolic & Immune Disorders - Drug Targets Beta-cell Specific Autoantibodies: Are they Just an Indicator of Type 1 Diabetes?
Current Diabetes Reviews Vitamin D Insufficiency and Diabetes Risks
Current Drug Targets Underlying Pathways for Interferon Risk to Type II Diabetes Mellitus
Current Diabetes Reviews Editorial [Hot Topic:Continuous Glucose Monitoring Systems: Toys or Tools (Guest Editor: Christophe De Block)]
Current Diabetes Reviews Why Not to Use the Handgrip Test in the Assessment of Cardiovascular Autonomic Neuropathy Among Patients with Diabetes Mellitus?
Current Vascular Pharmacology Model-Based Insulin and Nutrition Administration for Tight Glycaemic Control in Critical Care
Current Drug Delivery Thromboprophylaxis in Medical Patients: An Update
Vascular Disease Prevention (Discontinued) Static Cerebral Blood Flow Autoregulation in Humans
Current Hypertension Reviews Design of Bioartificial Pancreas with Functional Micro/Nano-Based Encapsulation of Islets
Current Pharmaceutical Biotechnology Optic Nerve and Cerebral Edema in the Course of Diabetic Ketoacidosis
Current Neuropharmacology Applications and Limitations of Genetically Modified Mouse Models in Drug Discovery and Development
Current Drug Metabolism Early Risk Factors for Nonadherence in Pediatric Type 1 Diabetes: A Review of the Recent Literature
Current Diabetes Reviews Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Current Topics in Medicinal Chemistry Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Association Between Intra-Hospital Uncontrolled Glycemia and Health Outcomes in Patients with Diabetes: A Systematic Review of Observational Studies
Current Diabetes Reviews Equilibrative Nucleoside Transporters in Fetal Endothelial Dysfunction in Diabetes Mellitus and Hyperglycaemia
Current Vascular Pharmacology Cerebrovascular Complications of Diabetes: SGLT-2 Inhibitors as a Promising Future Therapeutics
Current Drug Targets